Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Noritaka Tanaka, W. Marston Linehan, Chendi Li, et al.
Cancer Discovery (2021) Vol. 11, Iss. 8, pp. 1913-1922
Open Access | Times Cited: 372

Showing 1-25 of 372 citing articles:

Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang, Roy S. Herbst, Chris Boshoff
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1345-1356
Closed Access | Times Cited: 700
KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 600
Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 554
Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2382-2393
Open Access | Times Cited: 441
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 306
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. 160-166
Open Access | Times Cited: 260
Rational combinations of targeted cancer therapies: background, advances and challenges
Haojie Jin, Liqin Wang, René Bernards
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 213-234
Closed Access | Times Cited: 246
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 199
Patient-derived xenograft models in cancer therapy: technologies and applications
Yihan Liu, Wantao Wu, Changjing Cai, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 178
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 176
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
T. Koga, Kenichi Suda, Toshio Fujino, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 175
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 161
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Samuel A. Kerk, Thales Papagiannakopoulos, Yatrik M. Shah, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 8, pp. 510-525
Open Access | Times Cited: 155
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 154
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 154
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 153
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 141
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 132
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 130
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
James T. Coates, Sheng Sun, Ignaty Leshchiner, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2436-2445
Open Access | Times Cited: 126
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, et al.
Science (2023) Vol. 381, Iss. 6659, pp. 794-799
Open Access | Times Cited: 122
Circulating tumor DNA: current challenges for clinical utility
Donna K. Dang, Ben Ho Park
Journal of Clinical Investigation (2022) Vol. 132, Iss. 12
Open Access | Times Cited: 116
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1556-1571
Open Access | Times Cited: 104
Chasing molecular glue degraders: screening approaches
Ana Domostegui, Luis Nieto‐Barrado, Carles Perez‐Lopez, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5498-5517
Open Access | Times Cited: 103
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 92
Page 1 - Next Page

Scroll to top